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A functionally normal TP53 is essential to protect organisms
from developing cancer. Somatic mutations in the gene
represent one of the highest recurring perturbations in
human tumours, including colorectal cancer (CRC). How-
ever, the variegated phenotype of wide spectrum of somatic
mutations in TP53 and the complexity of the disease prevent
a straight interpretation of the mutational analysis in
tumours. In addition to the presence of somatic mutations,
polymorphic features of the gene may also contribute to
alteration of the normal TP53 functioning and variants,
mainly in the form of single nucleotide polymorphisms, can
be expected to impact susceptibility to sporadic CRC. In the
present study, we reviewed the potential role of alterations
in the TP53 gene, both somatic mutations and inherited
sequence variations, in predisposition to CRC and in the
prognosis and response to therapy. The available data from
association studies have mostly shown contradictory out-
comes. The majority of the studies were based on limited
sample sizes and focussed on a limited number of poly-
morphisms, with main being the rs1042522 (Arg72Pro).
Thus far, there is no possible generalisation of the role of
TP53 as also a predictor of therapeutic response and
prognosis. The effects of TP53, and its abnormalities, on the
response of tumours to cytotoxic drugs, radiation and
chemoradiation are complex. However, from studies it is
emerging that the inherited genetics of TP53 pathway
components could be utilised to further define patient
populations in their abilities to induce p53 activity in
response to either DNA damaging or p53-targeted therapies.
TP53 gene and colorectal cancer
The tumour suppressor TP53 (MIM# 191170), located on
chromosome 17p13.1, owing to diverse functions is known as
‘the guardian of the genome’ or ‘the cellular gatekeeper of
growth and division’ (1,2). The gene contains 11 exons and
transcribes a 2.8 kb mRNA, which is translated into a 53 kDa
protein. p53, a 393 amino acid long phosphoprotein, acts as
a key regulator of cellular growth control and plays a central
role in the induction of genes that are important in cell cycle
arrest and apoptosis following DNA damage (3). p53 under-
goes several post-translational modifications that regulate its
stability and its subcellular localisation (3,4).
The ability of p53 to prevent cell growth is pivotal to its
tumour suppressor functions. Newly synthesised p53 accumu-
lates in cytoplasm during G1, enters nucleus during G1–S
phase transition and finally cycles back to the cytoplasm during
S phase (5). The function of p53 is to reduce the risk of
malignant transformation through apoptosis in cells with
oncogenic activation. DNA damage and/or genotoxic stress
reportedly cause p53 induction, which dependant on the
context, results either in growth arrest or apoptosis (6). Cell
cycle arrest, induced by p53 through transcription of down-
stream effectors, provides time window for the cell to repair
genomic damage before entering the critical stages of DNA
synthesis and mitosis. The arrested cells can be released back
into the proliferating pool through various biochemical functions
involving p53 (7).
TP53 is one of the most frequently mutated genes in human
cancers. The most common mutations are single base
substitutions that alter protein function. Some of the mutations
being oncogenic confer gain-of-function properties. Germline
mutations in TP53 occur in families with Li–Fraumeni
syndrome, which is associated with an increased risk of
developing various cancers with an early age of onset (8).
Somatic mutations at specific residues have been associated
with specific clinical phenotypes in different type of cancer (9).
In addition to being frequently mutated in cancers, the gene is
also highly polymorphic. The fact that some germline variants
in the gene may modulate the individual susceptibility to
develop cancer has evinced particular interest for the potential
use as predictive markers (7).
Colorectal cancer (CRC) (MIM: 114500), which is rather
a common cancer, constitutes a significant proportion of the
global burden of cancer morbidity and mortality (10). The
worldwide incidence and mortality are estimated to be of 1.23
million new cases and 608 000 deaths in 2008 (11). Based on
investigation of different stages of tumour initiation and
progression, Fearon and Vogelstein proposed a model of
colorectal carcinogenesis that correlated specific genetic events
with evolving tissue morphology (12). Every step from normal
mucosa to carcinoma involves specific and well-defined
genetic alterations. This linear model has evolved to a more
complex, comprehensive and mechanistic approach (13).
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Characteristic alterations according to the model involve
tumour suppressor genes, APC, TP53 and DCC, and mutations
in the K-ras oncogene are characteristic of that model. The
mutations in TP53 or its loss of function mainly occur at the
transition from adenoma to cancer and the frequency of
alterations in the gene increases with the corresponding
progression of the lesion (14).
TP53 mutations in CRC
The reported frequency of mutations in TP53 in CRC is 50%,
and those affect mainly five ‘hotspot’ codons that include 175,
245, 248, 273 and 282 (15–17). Mutation in codon 175
reportedly occurs at a high frequency in tumours located in the
colon and the mutation involving the codon 288 in exon 8 is
more common in rectal tumours (18). Interestingly, mutations
occurring in the conserved regions of TP53 are more frequent
in tumours located at the distal compared to proximal colon
and this has been suggested to reflect differences in the
aetiology of CRC (19). Transversion (purine to pyrimidine)
rather than transition (purine to purine, pyrimidine to
pyrimidine) mutations are also reported to occur more
frequently in distal colon tumours (20). Mutations in colorectal
adenomas are rather rare (16% in adenomas versus 40–50% in
CRC), as stated before, the alterations in the gene represent
a late event in adenocarcinoma progression (21). Based on
mutational data from 9000 colorectal tumours the most
frequent mutations observed in both adenocarcinomas and
carcinomas have been at codons 175 and 273. However, the
observed frequency of mutation at codon 248 has been reported
approximately three times higher in adenocarcinomas than in
adenomas (22). TP53 mutational status in CRC appears to be
connected with the age of the patients at diagnosis, but a clear
explanation owing to contradictory results is lacking (23).
TP53 variants and CRC risk
Hitherto, 200 single nucleotide polymorphisms (SNPs) in the
TP53 gene have been identified (http://www-p53.iarc.fr/).
Because of relatively high frequencies of the variant alleles
in general population, most of the variants in TP53 are unlikely
to have more than subtle biological effects. Out of the 19
exonic polymorphisms, 8 are synonymous, which could,
theoretically affect protein expression, folding and function
as well as cause alternative splicing. Four out of 11 non-
synonymous polymorphisms have been validated and are
included in databases (HAPMAP, IARC). A large number of
all variants are actually localised in introns of the gene (7).
The most investigated polymorphism is rs1042522, a G to C
transversion in codon 72 of exon 4, which results in an amino
acidic change from arginine to proline (TP53 Arg72Pro). The
rs1042522 polymorphism is located in a proline-rich region of
the protein, which has been known for long to be important for
the growth suppression and apoptotic functions (24). The
polymorphism results in a structural change in the protein
giving rise to variants of distinct electrophoretic mobility (3).
The two isoforms of p53 due to polymorphism at codon 72
differ in biochemical and biological properties. Apparently, the
TP53 Arg72 form induces apoptosis more efficiently than the
Pro72 form (25,26). The Arg72 variant, when in cis-form with
certain tumour-derived mutations, might enhance tumour
suppressive function owing to increased ability to inactivate
p73. Those gain-of-function mutations are obviously influ-
enced by the polymorphism and mutated TP53 Arg72 bind p73
more efficiently than the mutated TP53 Pro72 (27).
A number of studies have investigated the role of
the presumptively functional Arg72Pro polymorphism in
modulation of cancer risk. As indicated by several meta-
analyses, Arg72Pro variant has been observed to be involved in
susceptibility to breast, lung and gastric cancers but not
cervical cancer (28–31). However, the epidemiological studies
on association of risk with Arg72Pro polymorphism have not
yielded consistent results. One of the plausible reasons for
the observed inconsistency can be differential behaviour of the
variant proteins in the absence or presence of mutations in the
tumour. The simultaneous presence of Arg72 allele in mutated
form of TP53 (mTP53) may serve as a predictor of enhanced
tumour development due to inactivation of p73. On the other
hand, Arg72 allele over wild type (wtTP53) background might
potentially increase apoptotic ability. A modifier effect of the
Arg72Pro SNP has also been reported in germline TP53
mutation carriers, where Arg72 was associated with an earlier
age at first diagnosis of cancer (32).
Significant differences in allele frequencies for the
rs1042522 polymorphism between different ethnic groups
have been observed. The frequency of Pro72 allele is reported
60% in African Americans and 30–35% in Caucasian
Americans. Interestingly, the Pro72 allele frequency increases
in a linear manner in multiple populations in a North to South
gradient towards equator raising the possibility of a selection in
areas of high ultraviolet light exposure (33). However, no
significant correlation between the Arg72 allele frequency and
the latitude was observed in additional 12 populations tested
later in insular Southeast Asia and Oceania (34). The SNP on
codon 72 has been also associated with a significant selection
signal for some climate variables, such as short-wave radiation
flux in winter, the associations did not remain statistical
significant once correction for multiple hypothesis testing
were applied in 971 unrelated individuals from 52 unique
populations worldwide (35).
Several investigations have so far examined the association
between the Arg72Pro polymorphism and the modulation of
CRC risk including studies on risk of adenoma. The majority
of the studies are based on Caucasian populations; six
investigated Chinese, African and Afro-American ethnicities
(Table I). Six studies have reported the association of CRC risk
with Pro72 allele (36,38,39,46,47,50,54) and one with risk of
adenoma (50). One study explored the association between
colon cancer and 94 SNPs in 63 genes and used polymorphism
interaction analysis to examine all possible combinations in
216 colon cancer patients to predict the risk. From that study it
emerged that the GSTT1 null genotype in combination with the
TP53 Pro72 allele significantly increased the risk (47). In
addition to the observed statistically significant risk of cancer
in the carriers of the Pro72 allele, the risk was particularly more
pronounced in alcohol consumers (46). In contrast, two studies
described association of the Arg72 allele with an increased risk
(43,49) and one study showed increased adenoma risk (48).
Interestingly, one of those studies also showed the highest
frequency of Arg/Arg genotype in individuals with Dukes C
and D stage of CRC (49). Similar results had been reported
earlier (55). The statistically significant association was also
observed for Arg72 allele homozygotes when only cancer in
left colon (descending and sigmoideum) was considered (43).
Meta-analyses have been recently conducted to evaluate the
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Song et al. (36) Arg72Pro 1829 CRC 1700 Asian (Korea) Pro72
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Joshi et al. (37) Arg72Pro 685 CRC 778 Asian (Japan) No association
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Kruger et al. (51) Arg72Pro 126 CRC 245 Caucasian (Germany) No association




77 Not known No association
Sotamaa et al. (53) Arg72Pro 186 CRC
(stratified for different
MSI status)
323 Caucasian (Finland) No association in any
of the subgroups
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potential association of the codon 72 polymorphism specifi-
cally with CRC risk (57,58) or with digestive tract cancers (59)
or with cancer susceptibility in general (60). In none a clear
strong effect of this polymorphism on the risk of CRC emerged
and these results are consistent with other studies reporting no
association (37,41,42,51,53,55). One of the limitations of
those studies has been the lack of information about potential
gene–gene or gene–environment interactions (58).
Another frequently studied TP53 polymorphism is 16-bp
duplication in intron 3 (PIN3, rs17878362: the different alleles
are called A1 and A2, with A2 carrying the 16-bp duplication). A
reduced amount of steady-state RNA for the variant A2 allele in
immortalised lymphoblastoid cell lines compared to the common
allele was reported. These results were confirmed with mRNA
extracted directly from patient’s lymphocytes (54). Previously,
other investigators have reported that the A2 allele was
associated with decreased apoptosis and DNA repair in
lymphoblastoid cell lines (61). Consistent with these altered
functional activities, several studies have correlated the intron
3 duplication with an increased risk of various cancers including
lung, breast and ovary (61–65). Other groups failed to confirm
those results (66,67).
Six studies examined the association between the TP53 PIN3
polymorphism and CRC risk and one investigated the risk
adenoma (Table I). While two studies showed association
between the decreased risk and A2 allele, another case-control
study reported association with increased risk (44,54,56). Due to
the strong linkage disequilibrium between intron 3 duplication
and the codon 72 variant, it has not been discerned whether the
intron 3 polymorphism alone influences mRNA stability or the
effect is modulated by the presence of the Pro72 variant (54). At
the same time, other investigations have failed to confirm
association with increased risk in other populations with similar
ethnicities (40,45,50). In an Italian population, PIN3 A2 allele
was associated with an increased risk of colorectal adenomas but
not CRC (50). No significant differences were observed between
cases and controls in the two by far largest studies (40,45).
Interestingly, a protective effect towards CRC risk was found
only among PIN3 A1 allele carriers, who also used non-steroidal
anti-inflammatory drugs (NSAIDs) (45).
Despite the large number of polymorphisms identified in the
TP53 gene, only few other variants have been analysed for
association with CRC risk (Table I). No association was found
with rs17880604 polymorphism in intron 6 (IVS6  36G . C;
G13964C) (44,52,56). In one study, the carriers of the variant
A-allele for the rs17884306 polymorphism in exon 11 (363G .
A) were found to be at a decreased risk of rectal cancer, while no
significant association was observed with the rs12947788 (IVS7
þ 72C . T) polymorphism (40).
Haplotype analysis
As evident, the contribution of individual genetic variants to
the predisposition to a disease is likely to be minor and difficult
to ascertain in small-sized studies with insufficient statistical
power. In a modified approach, haplotype analysis has been
suggested as a promising method for studying cancer-gene
associations (68). It is possible that instead of individual
polymorphisms, certain sets of haplotypes comprised several
variants, within critical genes/loci exhibit a differential asso-
ciation with cancer susceptibility (69). It is assumed that these
associations, and the identification of a few alleles of
a haplotype block, can unambiguously identify all other
polymorphic sites in the particular region, since the integration
of an increasing number of common genetic variations in the
analysis enables an increased statistical power in such studies.
Interestingly, evidence about the relevance of specific TP53
haplotypes on the regulation of the expression of different
isoforms of the gene has emerged. An evidently cooperative
effect between SNPs within the internal promoter thus
emphasises the potential of inter-individual differences (70).
So far, only four studies have reported haplotype analyses
based on TP53 polymorphisms in association with CRC risk,
one also investigated risk of adenoma. In two of the studies, the
haplotypes included only PIN3 and Arg72Pro polymorphisms
and another study also included a polymorphism in intron 6
(45,50,56). A haplotype analysis based on four polymorphisms
was carried out in a large study that provided an extended
coverage of the linkage disequilibrium block (40). In an earlier
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tumours with [ LOH





Sjalander et al. (56) Arg72Pro 155 CRC 206 Caucasian (Sweden) PIN3 A2 allele with Y
CRC risk
A2-Pro72 haplotype




Studies are in chronological order from the most recent to the oldest one. rs numbers for polymorphisms: Arg72Pro rs1042522, PIN3 rs17878362, IVS7 þ 72C . T
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aFor PIN3, the different alleles are called A1 and A2, with A2 carrying the 16-bp duplication.
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risk of CRC; the A2-Pro72 haplotype was statistically
significantly less frequent in CRC patients compared to
controls (56). A differential distribution of the haplotypes
based on the PIN3 and Arg72Pro polymorphisms was observed
between 467 CRC cases and 563 controls but only the A1-
Arg72 haplotype was associated with an increased CRC risk
(45). Additionally, patients with the A2-Pro72 haplotype and
without regular use of NSAIDs were at statistically sig-
nificantly decreased risk of CRC (45). A different distribution
of the two most common haplotypes between cases and
controls was observed in another study that included four
polymorphisms of TP53. In particular, A1-Arg72-C-G and A2-
Pro72-C-G were present in 81% of cases and only in 72% of
controls in a total population of 614 CRC cases and 614
colonoscopy negative controls. The A2-Pro72-C-G haplotype
was also associated with an increased risk of CRC when
compared with the most common haplotype with only common
alleles (A1-Arg72-C-G). Four other less represented haplotypes
(A1-Pro72-C-G, A2-Arg72-C-G, A1-Arg72-T-G and A1-
Arg72-C-A) were associated with significantly decreased risk.
Moreover, the most common haplotype, A1-Arg72-C-G, when
compared to all other haplotypes, was associated with an
increased CRC risk (40).
TP53 somatic mutations and gene variants: prognostic and
predictive significance in CRC
Many studies have reported association of somatic mutations in
TP53 or abnormal protein expression with poor survival or lack
of response to therapy. However, the clinical significance of
TP53 status still remains controversial (71–73). Not only the
complexity of the TP53 pathway, the abundance of mutations
in different tumour types and clinical stages, and their disparate
effects but also the lack of randomised prospective studies, that
are compounded by heterogeneity of experimental designs,
sample types and techniques make a generalised conclusion
difficult. At the same time, it would perhaps be a presumptive
expectation that a ubiquitously mutated gene would have the
same clinical value regardless of the context (74). Structural
and functional features of p53 might be useful as a molecular
prognostic marker (75). It is worth taking into consideration
that ‘only’ 50% of human tumours carry TP53 mutations.
Nevertheless, it is assumed that the pathway is inactivated
through alterations in upstream and downstream affectors of
the gene (76).
Survival predictions based on TP53 mutational status have
been observed for some malignancies. In the cancers of breast,
head and neck, liver, haematopoietic and lymphoid systems,
a majority of studies have associated TP53 mutations with
worsened survival. However, in the case of cancers of the
bladder, brain, lung, oesophagus and ovary, data are in-
consistent (18,77–82). The majority of studies on the clinical
relevance of TP53 polymorphisms mainly focused on the role
of Arg72Pro. The Arg72 variant has been reported to be a more
potent inhibitor of chemotherapy-induced apoptosis than the
corresponding Pro72 variant (83). Patients, homozygote for
Arg72 allele, with breast, lung or head and neck cancers have
been shown to survive and respond better to chemotherapy and
radiotherapy (84–87).
Several studies, generally with small patient numbers, have
investigated the link between specific TP53 mutations or
immunohistochemical status of the protein and the prognosis
and response to cancer treatment (88). In a large population-
based study, tumours with mTP53 were shown to be associated
with a significantly worse 5-year survival than those with
wtTP53. A significantly worse prognosis was also observed for
patients with specific types of mutations and mutations in
proximal tumours. In multivariate analyses, however, the only
significant predictors of poor prognosis were G245 hotspot
mutation and mutations in proximal tumours (20).
In a review based on 18766 CRC patients from 168 studies
on the effect on prognosis association of increased risk of death
was observed, after correction for heterogeneity and publica-
tion bias, with both abnormal and mutated p53 (71). Another
study comprised 3583 patients from 25 research groups in 17
countries and showed higher frequency of TP53 mutations in
distal and rectal than in proximal tumours; mutations were
associated with lymphatic invasion in proximal tumours; amino
acid loss causing mutations were associated with worse
survival and patients with Dukes’ C tumours with wild type
TP53 showed better survival after treatment with adjuvant
chemotherapy (89).
A few other studies have investigated the effect of TP53 on
CRC prognosis in specific subcategories including those with
specific mutations, with concomitant mutations in other
relevant genes, MSI status and cancer site/stage (90–94). In
a study on 353 sporadic CRC patients, mutation in codon 175
of exon 5 conferred a better prognosis, while alterations in
exon 8 were related with worse prognosis in different
subgroups of patients that included men, patients younger than
71 years old, tumours located in the proximal colon,
moderately differentiated and mucinous (18). Both mTP53
and MSI-H resulted to be prognostic indicators for disease-free
survival, but only TP53 retained statistical significance after
adjustment for clinical heterogeneity as shown in a study based
on 220 tumours. Additionally, mTP53 was associated with
a short disease-free survival, whereas KRAS mutations did not
show any prognostic significance (95).
Dukes’ B stage patients who were carriers of the variant
Pro72 allele over GSTM1 null background had poor chance of
survival in a study based on 102 patients compared to patients
homozygotes for Arg72 allele and GSTM1 positive (41). The
prognostic value of Arg72Pro polymorphism in colorectal
adenocarcinoma may also be dependant on patient race/
ethnicity. The analysis of Arg72Pro polymorphism in African
American and Caucasian CRC patients showed a higher
frequency of the Pro/Pro genotype in the former that associated
with an increased frequency of TP53 mutations, with advanced
tumour stage and with short survival (96).
The effects of TP53, and its abnormalities, on the response
of tumours to cytotoxic drugs, radiation and chemoradiation
are complex and it is, perhaps, unrealistic to expect
a straightforward relationship between any mutation in TP53
and the response to treatment with chemotherapy (97). In
particular, 5-fluorouracil (5-FU) is widely used in the treatment
of a range of cancers and has shown largest impact on CRC.
TP53 can be activated by 5-FU through more than one
mechanisms including incorporation of fluorouridine triphos-
phate into RNA, fluorodeoxyuridine triphosphate into DNA
and inhibition of thymidylate synthase with resultant DNA
damage (98). TP53 status expectedly appears to have pre-
dictive value for the survival of CRC patients receiving 5-FU
chemotherapy. Previous in vitro and clinical investigations
reported that CRC patients with wtTP53 tumours benefit from
5-FU-based chemotherapy, while those with mutated gene
tumours do not (99–101). Recent studies evaluated the findings
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in well-defined patient cohorts and treatment modalities
[reviewed by Robles and Harris (74)].
mTP53 has been shown to be a predictor of better clinical
outcome in patients with chemotherapy-refractory metastasis
treated with the anti-epidermal growth factor receptor (anti-
EGFR) antibody cetuximab in a study based on 64 metastatic
patients. TP53 mutations are predictive markers of cetuximab
sensitivity, particularly for patients without detectable KRAS
mutation that confers a better response to therapy and time to
progression (102). TP53 mutations and better clinical outcome
may appear to be unexpected because most of studies have
shown an opposite association with a worse prognosis in stage
II–III CRC patients (95). However, the predictive function of
TP53 mutations in metastatic CRC patients treated with
targeted therapies has not been so far established. The only
previous study performed on metastatic CRC in the context of
targeted therapies involved anti-vascular endothelial growth
factor (anti-VEGF) antibody bevacizumab that showed no
correlation between TP53 status and the clinical response
(103). Another study on 93 stage IV CRC patients with
unresectable liver metastasis receiving exclusively 5-FU
therapy did not find any association with KRAS status and
TP53 alterations (104).
Thus, additionally to TP53 mutations, both in combinations
and independently, the role of polymorphisms (mainly
Arg72Pro polymorphism) in the gene has attracted an interest
in the response to CRC therapy. In vitro studies using various
p53-inducible isogenic cell lines showed the greater apoptotic
potential of Arg72 allele both in the presence and in the
absence of chemotherapeutics (105). In one study, Arg/Arg
genotype of Arg72Pro polymorphism without TP53 mutations
was shown to predict a more favourable response to 5-FU-
based chemotherapy compared to same genotype with
inactivating TP53 mutations (17). There is an indication of
emerging evidence in the literature that suggests that probably
inherited genetics of TP53 pathway components could also be
utilised to further define patient populations in their abilities to
induce p53 activity in response to either DNA damaging or
p53-targeted therapies. Studies have shown that restoration of
wild type p53 activity in human tumours could be employed in
cancer therapy (106).
Conclusions
TP53 is a key regulator gene controlling several important
cellular pathways, such as cell cycle control, apoptosis, DNA
repair, and is involved in maintaining the genomic integrity.
The findings that TP53 mutations can occur early in
carcinogenesis, and that p53 can have a molecular signature
based on the type of cancer and exposure linked to that cancer,
make it an attractive target as an intermediate biomarker. In
CRC, the alteration of the normal function of this gene also
represents an important step in carcinogenesis although
mutations are identified as late events in the process. It is
assumed that TP53 mutations may help cells to cope with
stress-induced tissue remodelling constraints, providing
a short-term proliferative advantage, which probably leads to
an enhanced risk of progression to cancer. Due to the
fundamental role of TP53, naturally occurring variants are
also expected to play a role in the susceptibility to sporadic
CRC. Elucidation of the effect of TP53 polymorphisms on the
risk of CRC is a challenge, which is attracting an interest in the
recent years. No uniform conclusion can be drawn for roles of
polymorphisms and mutations in the TP53 gene as results are
so far inconsistent. Further, large studies on different ethnicities
investigating a wider spectrum of TP53 variants are warranted
with inclusion of haplotype-tagging approach. Despite impres-
sive progress in mechanistic understanding of p53 structure and
function, p53 research has not yet generated applications of
wide impact on cancer management and therapy. It is highly
unlikely that p53 alterations could serve as a clinically useful,
routine marker of prognosis for CRC. However, it could find
clinical application for the identification of patients who might
benefit from 5-FU-based chemotherapy.
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